Regenerative Medicine

Regenerative medicine has become one of the most heavily promoted areas of hair loss treatment, but the term includes therapies with very different levels of scientific evidence and regulatory oversight.

These approaches generally attempt to influence existing hair follicles through platelets, growth factors, cells or biological signaling molecules. They should not be confused with creating entirely new follicles. At present, there is no established regenerative treatment that can reliably generate a new population of fully functional human scalp hair follicles.

The best studied treatment in this category is platelet-rich plasma, or PRP. Other approaches, including exosomes and cell-derived therapies, remain considerably more experimental.

Regenerative treatments should therefore be evaluated individually rather than grouped together simply because they are described as “stem cell,” “exosome” or “regenerative” therapies.

PRP has a growing clinical evidence base, particularly in androgenetic alopecia, although preparation methods and treatment protocols vary substantially. Exosome, adipose-derived and umbilical cord-derived approaches have a much smaller and less standardized body of human evidence.

No exosome or stem-cell product is FDA approved for the treatment of hair loss. Commercial availability also does not establish that a product is FDA approved, clinically effective or equivalent to a preparation used in published research.

The source of the material, how it is processed, what it actually contains and the quality of the human clinical evidence all matter.

Education - 

Research - 

Commitment